Format

Send to

Choose Destination
Viruses. 2014 Oct 24;6(10):4095-139. doi: 10.3390/v6104095.

Current perspectives on HIV-1 antiretroviral drug resistance.

Author information

1
Department of Pharmacology, School of Medicine, Yale University, New Haven, CT 06520, USA. pinar.iyidogan@yale.edu.
2
Department of Pharmacology, School of Medicine, Yale University, New Haven, CT 06520, USA. karen.anderson@yale.edu.

Abstract

Current advancements in antiretroviral therapy (ART) have turned HIV-1 infection into a chronic and manageable disease. However, treatment is only effective until HIV-1 develops resistance against the administered drugs. The most recent antiretroviral drugs have become superior at delaying the evolution of acquired drug resistance. In this review, the viral fitness and its correlation to HIV-1 mutation rates and drug resistance are discussed while emphasizing the concept of lethal mutagenesis as an alternative therapy. The development of resistance to the different classes of approved drugs and the importance of monitoring antiretroviral drug resistance are also summarized briefly.

PMID:
25341668
PMCID:
PMC4213579
DOI:
10.3390/v6104095
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center